InMed Pharmaceuticals (INM) Other Working Capital Changes (2022 - 2026)
InMed Pharmaceuticals' (INM) quarterly Other Working Capital Changes came in at -$110066.0 in Q1 2026, up 1.11% year-on-year from -$108861.9 in Q1 2025, and little changed quarter-over-quarter from -$109917.0 in Q4 2025.
InMed Pharmaceuticals (INM) Other Working Capital Changes (2022 - 2026) Analysis & Trends
InMed Pharmaceuticals' Other Working Capital Changes history runs 4 years deep, the most recent figure standing at -$110066.0 for Q1 2026.
- On a quarterly basis, Other Working Capital Changes rose 1.11% year-over-year to -$110066.0 in Q1 2026; TTM through Mar 2026 was -$442054.0, a 950.26% decrease from a year earlier, with the FY2025 full-year figure at -$429880.0, down 2558.34% from the prior year.
- Other Working Capital Changes held at -$110066.0 in Q1 2026 per INM's latest filing, from -$109917.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $495104.0 in Q4 2024 and bottomed at -$328867.0 in Q3 2024.
- The 4-year median for Other Working Capital Changes is -$8902.0 (2022), against an average of $30502.8.
- Biggest YoY gain for Other Working Capital Changes was 350.38% in 2024; the steepest drop was 187.61% in 2024.
- Year by year, Other Working Capital Changes stood at $111194.0 in 2023, then slumped by 187.61% to -$97418.0 in 2024, then decreased by 12.83% to -$109917.0 in 2025, then fell by 0.14% to -$110066.0 in 2026.
- Per Business Quant, the three latest INM Other Working Capital Changes figures stand at -$110066.0 (Q1 2026), -$109917.0 (Q4 2025), and -$107412.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | InMed Pharmaceuticals | 307,858.50 | -4.93 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42,225.00 |
| Mar 31, 2026 | -42,225.00 |
| Mar 31, 2026 | -42,225.00 |
| Dec 31, 2025 | 467,042.00 |
| Dec 31, 2025 | 467,042.00 |
| Dec 31, 2025 | 467,042.00 |
| Sep 30, 2025 | -129,992.00 |
| Sep 30, 2025 | -129,992.00 |
| Sep 30, 2025 | -129,992.00 |
| Mar 31, 2025 | -104,656.00 |
| Mar 31, 2025 | -104,656.00 |
| Mar 31, 2025 | -104,656.00 |
| Dec 31, 2024 | 495,104.00 |
| Dec 31, 2024 | 495,104.00 |
| Dec 31, 2024 | 495,104.00 |
| Sep 30, 2024 | -328,867.00 |
| Sep 30, 2024 | -328,867.00 |
| Sep 30, 2024 | -328,867.00 |
| Mar 31, 2024 | -28,656.00 |
| Mar 31, 2024 | -28,656.00 |